CARBAMAZEPINE AND PHENYTOIN IN EPILEPSIES REFRACTORY TO BARBITURATES - EFFICACY, TOXICITY AND MENTAL FUNCTION

被引:18
作者
BITTENCOURT, PRM
ANTONIUK, SA
BIGARELLA, MM
DACOSTA, JC
DORO, MP
FERREIRA, AS
FONSECA, LC
GORZ, AM
SILVA, GEG
MARCOURAKIS, T
TEDROS, GMAS
机构
[1] CATHOLIC UNIV CAMPINAS,CAMPINAS,SP,BRAZIL
[2] UNIV SAO PAULO,CTR INVEST NEUROL,SAO PAULO,SP,BRAZIL
[3] FED UNIV PERNAMBUCO,RECIFE,PE,BRAZIL
[4] CATHOLIC UNIV PORTO ALEGRE,PORTO ALEGRE,RS,BRAZIL
关键词
ANTIEPILEPTIC DRUGS; CONTROLLED TRIAL; BARBITURATES; PHENYTOIN; CARBAMAZEPINE; PARTIAL SEIZURES; COGNITIVE FUNCTION; PSYCHOPATHOLOGY;
D O I
10.1016/0920-1211(93)90029-7
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
A group of 51 patients with chronic cryptogenic or symptomatic localized epilepsy refractory lo therapy with barbiturates underwent progressive substitution with phenytoin or carbamazepine, in standardized and randomized fashion. After drug changes were completed two thirds of the patients remained seizure free during a period of 6 months. A clearer effect of phenytoin and carbamazepine was seen on secondary generalized than on partial seizures. The frequency of severe side effects decreased after the change to phenytoin and carbamazepine. The group on carbamazepine improved in immediate and late recall, and in immediate and late recognition of pictures. The group on phenytoin improved significantly in the Stroop test. Patients changed to phenytoin, but not those changed to carbamazepine, became significantly more aggressive, anxious and depressive than when on phenobarbital, as measured by subjective scales. The results indicate that patients should not be considered refractory to antiepileptic drug therapy while on barbiturates. Cognitive dysfunction and mood changes observed in epilepsy may be temporary and dependent on the presence of seizures and/or on use of barbiturates.
引用
收藏
页码:147 / 155
页数:9
相关论文
共 25 条
[1]   TIME-DEPENDENT PHARMACODYNAMIC EFFECTS OF PHENOBARBITAL IN HUMANS [J].
BARZAGHI, N ;
GATTI, G ;
MANNI, R ;
GALIMBERTI, CA ;
ZUCCA, C ;
TARTARA, A ;
PERUCCA, E .
THERAPEUTIC DRUG MONITORING, 1989, 11 (06) :661-666
[2]  
BIGARELLA M M, 1991, Arquivos de Neuro-Psiquiatria, V49, P136
[3]  
Bittencourt P R, 1992, Arq Neuropsiquiatr, V50, P24
[4]  
BITTENCOURT PRM, 1987, EPILEPSIA, V28, P582
[5]  
BITTENCOURT PRM, 1988, TXB EPILEPSY, P518
[6]  
BITTENCOURT PRM, 1990, INT EPILEPTOLOGY, P807
[7]  
Commission on Classification and Terminology of the International League Against Epilepsy, 1989, EPILEPSIA, V30, P389
[8]   COGNITIVE EFFECTS OF PHENYTOIN DURING MONOTHERAPY AND AFTER WITHDRAWAL [J].
GALLASSI, R ;
MORREALE, A ;
LORUSSO, S ;
FERRARI, M ;
PROCACCIANTI, G ;
LUGARESI, E ;
BARUZZI, A .
ACTA NEUROLOGICA SCANDINAVICA, 1987, 75 (04) :258-261
[9]  
Gorz A M, 1986, Arq Neuropsiquiatr, V44, P225
[10]  
GRIFFITHS RR, 1987, PSYCHOPHARMACOLOGY 3, P1535